32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC)

H-J Chen,J-J Yang,J Zhao,Y-P Sun,Q Wen,Q Zhou,Z Zhang,H-Y Tu,J-Y Zhou,P Zhang,X Chen,H-X Chen,Q Dang,M-H Sun,Y Li,Y-L Wu

doi:10.1016/j.annonc.2021.01.047

32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC)

H-J Chen, J-J Yang + Show 14 more

Open Access

https://doi.org/10.1016/j.annonc.2021.01.047

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Mar 1, 2021
License type: publisher-specific-oa

Affiliation: Guangdong Provincial People's Hospital, Peking University Cancer Hospital, Jinan Central Hospital, Zhejiang University

#MET Inhibitor #Selective c-MET Inhibitor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

SCC244 is a novel potent and highly selective c-MET inhibitor, which displayed high antitumor activity and desirable pharmacokinetic (PK) profile in preclinical models. This first-in-human phase I study was designed to evaluate the safety, PK, and preliminary efficacy of SCC244. Here, we reported the results from phase Ia part of the study.

Full Text